I never said CTIX was incapable. I think the move is a mistake. You are leaving out the logistical background regarding K, including prepping for the Phase II trials, interfacing with DF, and other items I probably can't conceive of myself.
B and the partnership by your own admission is also a drain on human capital, and I think B should be up there in priorities. Leo may not be doing the lab research but he oversees all regulatory fillings and the direction of the company, the addition of both compounds complicate that job further.
P is hardly on hold as they are filling INDs as we speak, as well as waiting on the patent and dealing with the bureaucracy there. Leo oversees the logistics on this as well.
ALL of CTIX's money is borrowed or at the expense of the shareholder via dilution. This is going to raise the overhead costs. CTIX is not Pfizer; it can't start all these studies and research willy nilly. Not without causing harm to our holdings. Raising the overhead of the company for unproven compounds is misguided.
I also never said it was fluff either, those are not my words. The idea that 'would you rather company never said anything?' is a false choice. I would rather have relevant PR's (within reason) released as information came available. I am okay with gaps as well. However, I never ever claimed that I would rather the company say nothing at all.
I prefer that the investigation into yet more new compounds be kept to a minimum to keep the overhead cost of CTIX low, because as I've said before. Every penny spent by CTIX is borrowed, usually at the expense of the shareholder.
So by that reasoning, the investigations into these two new compounds is unwelcome. The 10Q essentially said that the company lives from financing deal to financing deal. Every penny spent on this research shortens how long CTIX can hold out without diluting or borrowing further.
